[Fundamental and clinical studies on XXXX in pediatrics, with special reference to @entity8 ].

@entity1 @entity8 @entity294 @entity409 @entity2348 @entity2262 @entity2886 @entity2891 @entity631 @entity5579
Fundamental, clinical studies on @entity2891 ( @entity5579 ), a new synthetic antibiotic of @entity2886 was conducted to obtain results as follows. This preparation, 11.4-50 mg/kg was administered to 11 cases of @entity1 by intravenous drip infusion for 30 minutes, and serum levels were studied. The highest serum level at the completion of infusion was 40.0-138.0 mcg/ml. A dose response was observed. The half-life in serum averaged 1.55 hours except 2.4 hours observed with 1 case of @entity409 . When the urinary excretion during 30 minutes drip infusion was examined, the urinary recovery rate at 0-6 hours in 2 cases of @entity1 averaged 17.2% and was low at 5.3% in 1 case of @entity631 . In terms of the clinical effect on @entity2348 in pediatric field, @entity5579 proved effective in all of the 21 cases in which it was used alone. And it showed an excellent antibacterial activity against all the bacteria isolated from cases used as the subjects. When side effects were studied, @entity294 and slight @entity409 were observed, but all were transient. As a result of a study on the @entity8 of @entity5579 , @entity5579 was deemed as being a drug which hardly causes disturbance of renal tubules judging from the aspect of the beta-D-N-acetylglucosaminidase activity in urine and variations in the urine @entity2262 levels.
